Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023551 · ClinicalTrials.gov registry record · Early Phase 1
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
A Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma, sponsored by Sumitomo Pharma America.
- Active
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 9
- Study locations
NCT05023551: Active Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma, sponsored by Sumitomo Pharma America.
NCT05023551 is a Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma that is active but no longer recruiting, run by Sumitomo Pharma America. The registered enrollment target is 39 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (59% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05023551, a Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma, is active but no longer recruiting, sponsored by Sumitomo Pharma America.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a study of DSP-0390 in patients with recurrent high grade glioma.
Primary Outcome
Occurrence of DLTs by Incidence of TEAEs and SAEs, as assessed by NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG DSP-0390
Study Locations (9)
California
- University of California at San Francisco - San Francisco
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
New York
- Columbia University - New York
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Hokkaido
- Hokkaido University Hospital - Sapporo
Sakyo-ku
- Kyoto University Hospital - Kyoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2026-10-31 |
| Phase | Early Phase 1 |
What the registry record for NCT05023551 still lists
NCT05023551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which DSP-0390 is the first listed.
NCT05023551 lists 9 locations in 9 states (California, Massachusetts, Missouri).
Frequently Asked Questions
What is clinical trial NCT05023551 about?
NCT05023551 is a clinical study titled "Study of DSP-0390 in Patients With Recurrent High-Grade Glioma". This is a study of DSP-0390 in patients with recurrent high grade glioma.
What is the current status of trial NCT05023551?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2021-09-08. Estimated completion is 2026-10-31.
What conditions does trial NCT05023551 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, High Grade Glioma.
What interventions are being tested in trial NCT05023551?
The interventions under investigation include: DSP-0390 (DRUG).
Who is sponsoring clinical trial NCT05023551?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023551 being conducted?
This trial has 9 study locations across California, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05023551's enrollment target sits among peer trials
39 49th of 88 higher than 39 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of Pamiparib in Newly Diagnosed and rGBM
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI